If you have been reading about triple agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
=== Center for Biosecurity at UPMC === The Center for Biosecurity at UPMC (CBUPMC) is led by Thomas V. Inglesby, MD. Their mandate is to conduct "independent research, analysis, and nonpartisan policy recommendations" to serve as "resources for decision makers who are responsible for strengthening US planning, response, and resilience to catastrophic events."
Carbobenzyloxy (Cbz) group — Removed by hydrogenolysis: hydrogen and palladium on activated carbon, or lithium or sodium in liquid ammonia. p-Methoxybenzyloxycarbonyl (Moz or MeOZ) group – Removed by hydrogenolysis, more labile than Cbz tert-Butyloxycarbonyl (Boc) group — Removed by concentrated strong acid (such as HCl or CF3COOH), or by heating to >80 °C. Common in solid phase peptide synthesis. 9-Fluorenylmethyloxycarbonyl (Fmoc) group — Removed by base, such as 20–50 % piperidine in dimethylformamide (DMF) or N-Methyl-2-pyrrolidone, or 50% morpholine in DMF for sensitive glycopeptides. Common in solid phase peptide synthesis Allyloxycarbonyl group — Removed with complexes of metals like palladium(0) or nickel(0). Other amides:
The performance of these batteries depends on the characteristics of the material that makes up the cathode. Carbon materials have been widely used as cathodes because of their excellent electrical conductivities, large surface areas, and chemical stability. Especially relevant for lithium-air batteries, carbon materials act as substrates for supporting metal oxides. Binder-free electrospun carbon nanofibers are particularly good potential candidates to be used in electrodes in lithium-oxygen batteries because they have no binders, have open macroporous structures, have carbons that support and catalyze the oxygen reduction reactions, and have versatility. Zhu et al. developed a novel cathode that can store lithium and oxygen in the electrode they named nanolithia which is a matrix of carbon nanofibers periodically embedded with cobalt oxide. These cobalt oxides provide stability to the normally unstable superoxide-containing nanolithia. In this design, oxygen is stored as LiO2 and does not convert between gaseous and solid forms during charging and discharging. When the battery is discharging, lithium ions in nanolithia and react with superoxide oxygen the matrix to form Li2O2, and Li2O. The oxygen remains in its solid state as it transitions among these forms. The chemical reactions of these transitions provide electrical energy. During charging, the transitions occur in reverse.
Sources: en.wikipedia.org
In Thailand, soy sauce is called sii-íu (Thai: ซีอิ๊ว). Sii-íu kǎao (Thai: ซีอิ๊วขาว, 'white soy sauce') is used as regular soy sauce in Thai cuisine, while sii-íu dam (Thai: ซีอิ๊วดำ, 'black soy sauce') is used primarily for colour. Another darker-coloured variety, sii-íu wǎan (Thai: ซีอิ๊วหวาน, 'sweet soy sauce') is used for dipping sauces. Sɔ́ɔt prung rót (Thai: ซอสปรุงรส, 'seasoning sauce') is also commonly used in modern Thai cuisine.
With 68.6 million tons of cargo in 2011, the port of Le Havre is the second largest French seaport in trade volume behind that of Marseille and 50th largest port in the world. It represents 60% of total French container traffic with nearly 2.2 million Twenty-foot equivalent unit|EVP]s in 2011. At the European level, it is eighth largest for container traffic and sixth largest for total traffic. The Port receives a large number of oil tankers that transported 27.5 million tonnes of crude oil and 11.7 million tonnes of refined product in 2011. Finally, 340,500 vehicles passed through the Roll-on/roll-off terminal in 2010. 75 regular shipping lines serve 500 ports around the world. The largest trading partner of the port of Le Havre is the Asian continent which alone accounts for 58% of imports by container and 39.6% of exports. The rest of the traffic is distributed mainly to Europe and America. Le Havre occupies the north bank of the estuary of the Seine on the Channel. Its location is favourable for several reasons: it is on the most frequented waterway in the world; it is the first and last port in the North Range of European ports – the largest in Europe which handles a quarter of all global maritime trade. As a deepwater port, it is accessible to all types of ships whatever their size around the clock. At the national level, Le Havre is 200 kilometres (124 mi) west of the most populous and richest region in France: Île-de-France.
=== Dwarf sports === Dwarfs have support and compete in sport by a number of organizations nationally and internationally. They are included in some events in the athletics at the Summer Paralympics. The Dwarf Athletic Association of America and the Dwarf Sports Association UK provide opportunities for dwarfs to compete nationally and internationally in the Americas and Europe, respectively. The World Dwarf Games (WDG) are a multi-sport event for athletes of short stature. The WDG have been held every four years since 1993 and are the world's largest sporting event exclusively for athletes with dwarfism. The Dwarf Sports Association UK organizes between 5 and 20 events per month for athletes with restricted growth conditions in the UK. For instance, swimming and bicycling are often recommended for people with skeletal dysplasias, since those activities put minimal pressure on the spine. Since its early days, professional wrestling has had the involvement of dwarf athletes. "Midget wrestling" had its heyday in the 1950s–'70s, when wrestlers such as Little Beaver, Lord Littlebrook, and Fuzzy Cupid toured North America, and Sky Low Low was the first holder of the National Wrestling Alliance's World Midget Championship. In the next couple of decades, more wrestlers became prominent in North America including foreign wrestlers like Japan's Little Tokyo. Although the term is seen by some as pejorative, many past and current midget wrestlers including Hornswoggle said they take pride in the term due to its history in the industry and its marketability.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.